参芎葡萄糖注射液对中、重度慢性阻塞性肺疾病患者的临床影响  

Clinical Effect of Shenxiong Gluose Injection on Patients with Middle and Serious Chronic Obstructive Pulmonary Disease

作　　者：朱莉莉[1] 刘磊[1] 李玉[1] 李玉梅[1] 陈勐[1] 刘博[1] 秦丹丹[1] 李桂兰[1] 郑岩[1] 唐文丽[1] 

机构地区：[1]哈尔滨医科大学附属第四医院呼吸内科,黑龙江哈尔滨150001

出　　处：《中国伤残医学》2014年第7期12-14,共3页Chinese Journal of Trauma and Disability Medicine

基　　金：黑龙江省自然科学基金资助项目(D201146)

摘　　要：目的:观察参芎葡萄糖对中、重度慢性阻塞性肺疾病患者的疗效。方法:采用随机对照研究,参芎葡萄糖组使用参芎葡萄糖注射液,对照组使用5%葡萄糖注射液,观察临床疗效、监测肺功能、血气分析。结果:治疗第3个疗程,参芎葡萄糖组Po2、Dlco较治疗前平均增加了21.4 mmHg、22.7 mL/min/mmHg,二者统计学均有显著差异(P<0.05);改善率:参芎葡萄糖组为22.7%,对照组为0,二者统计学有显著差异(P<0.05)。恶化率:参芎葡萄糖组4.55%,对照组为12%,二者统计学有显著差异(P<0.05)。结论:参芎葡萄糖可降低中、重度COPD患者恶化率,提高改善率,一定疗程后可改善中、重度COPD患者的弥散功能,改善机体缺氧状态。Objective： To discuss clinical effect of shenxiong gluose injection on patients with middle and serious Chronic Obstructive Pul- monary Disease （COPD）. Methods. A randomized controlled clinical trail was conducted in patients with COPD. Shenxiong gluose group were treated by shenxiong gluose injection and contrast group were treated by 5 percent gluose injection. Clinical effect, pulmonary func- tion examination and blood gas analysis were done. Results： After third therapy course, shenxiong gluose group significantly provided im- provement with Po2 and Dlco, and averagely increased 21.4mmHg,22.7mL/min/mmHg respectively. Improvement rate： Shenxiong glu- ose group was 22.7% VS contrast group was 0（ P 〈 0.05 ）. Corruption rate ： Shenxiong gluose group was 4.55% VS contrast group was 12% （P 〈 0.05 ）. Conclusion：Shenxiong gluose injection could significantly increase improvement rate and decrease corruption rate, it could improve lung diffusion function and hypoxia status in patients with COPD at certain courses

关 键 词：参芎葡萄糖注射液 慢性阻塞性肺疾病 临床疗效 

分 类 号：R563[医药卫生—呼吸系统]